gene in people relapsing following remedy with the BCL2 antagonist venetoclax. 66 Resistance to those agents has been related to these mutations in close to 70% of cases, Though they tend to be subclonal as well as their distinct function leading to resistance has to be proven.Over the past decades, the number of people referred for allogeneic hema